Profile data is unavailable for this security.
About the company
Sun Pharmaceutical Industries Limited is an India-based specialty generic pharmaceutical company. The Company is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulation and active pharmaceutical ingredients (APIs). It produces a comprehensive, diverse and complementary portfolio of generic and specialty medicines targeting a wide spectrum of chronic and acute treatments. The Company's vertically integrated network enables it to produce a wide range of pharmaceuticals, including oncology, hormones, peptides, and steroidal drugs. The Company also has a product portfolio in RoW markets, including injectables, hospital products and retail products. It offers a variety of dosage forms, including orals, creams, ointments, injectables, sprays, and liquids. Its marketed specialty portfolio includes Ilumya/ Ilumetri, Winlevi, Levulan Kerastick + BLU-U, Absorica LD, Odomzo, Cequa, Bromsite, Xelpros, Yonsa, Sezaby and Sprinkle portfolio.
- Revenue in INR (TTM)474.45bn
- Net income in INR89.06bn
- Incorporated1993
- Employees41.00k
- LocationSun Pharmaceutical Industries LtdSun House, CTS No. 201 B/1,, Western ExpMUMBAI 400 093IndiaIND
- Phone+91 2 243244324
- Fax+91 2 243244343
- Websitehttps://sunpharma.com/
Mergers & acquisitions
| Acquired company | SUNPHARMA:NSI since announced | Transaction value |
|---|---|---|
| Taro Pharmaceutical Industries Ltd | 57.13% | 347.79m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Torrent Pharmaceuticals Ltd | 104.74bn | 15.03bn | 861.97bn | 13.57k | 57.31 | -- | 37.49 | 8.23 | 44.44 | 44.44 | 309.68 | -- | -- | -- | -- | 7,716,901.00 | -- | 6.70 | -- | 10.48 | 74.12 | 70.84 | 14.35 | 11.22 | -- | 6.32 | -- | 63.62 | 13.07 | 10.09 | 60.22 | 12.92 | -6.22 | 25.74 |
| Zydus Lifesciences Ltd | 186.81bn | 29.56bn | 942.84bn | 23.03k | 32.08 | -- | 25.54 | 5.05 | 29.21 | 29.38 | 184.58 | -- | -- | -- | -- | 8,113,133.00 | -- | 7.92 | -- | 12.61 | 66.21 | 60.14 | 15.81 | 12.89 | -- | -- | -- | 20.55 | 14.08 | 7.59 | -12.34 | 1.83 | -0.3532 | 11.38 |
| Mankind Pharma Ltd | 99.46bn | 17.27bn | 959.67bn | 18.47k | 55.61 | -- | 44.91 | 9.65 | 43.08 | 43.08 | 248.12 | -- | -- | -- | -- | 5,385,717.00 | -- | -- | -- | -- | 68.37 | -- | 17.68 | -- | -- | 144.35 | -- | -- | 12.44 | -- | -10.58 | -- | -- | -- |
| Divi's Laboratories Ltd | 74.93bn | 13.83bn | 984.60bn | 16.95k | 71.18 | -- | 56.17 | 13.14 | 52.11 | 52.11 | 282.31 | -- | -- | -- | -- | 4,420,514.00 | -- | 18.50 | -- | 20.48 | 59.23 | 57.21 | 18.46 | 27.90 | -- | -- | -- | 31.31 | -13.31 | 14.70 | -38.41 | 15.76 | 11.55 | 24.57 |
| Dr Reddy's Laboratories Ltd | 272.13bn | 52.28bn | 992.00bn | 24.83k | 18.99 | -- | 14.93 | 3.65 | 313.75 | 313.75 | 1,633.13 | -- | -- | -- | -- | 10,958,640.00 | -- | 9.68 | -- | 13.81 | 70.55 | 65.53 | 19.21 | 12.76 | -- | 48.92 | -- | 17.84 | 14.50 | 11.55 | 106.94 | 33.23 | 11.31 | 14.87 |
| Cipla Ltd | 253.50bn | 37.08bn | 1.09tn | 26.62k | 29.34 | -- | 22.41 | 4.29 | 45.92 | 45.92 | 313.91 | -- | -- | -- | -- | 9,524,760.00 | -- | 8.61 | -- | 10.60 | 65.16 | 57.97 | 14.77 | 11.17 | -- | 47.26 | -- | 19.05 | 4.55 | 8.38 | 11.33 | 14.71 | 7.70 | 23.16 |
| Sun Pharmaceutical Industries Ltd | 474.45bn | 89.06bn | 3.64tn | 41.00k | 40.86 | -- | 31.43 | 7.67 | 37.11 | 37.11 | 197.73 | -- | -- | -- | -- | 11,571,860.00 | -- | 6.31 | -- | 9.02 | 77.80 | 70.08 | 18.97 | 12.17 | -- | 52.77 | -- | 39.54 | 13.53 | 10.62 | 158.91 | 29.24 | 1.24 | 41.88 |
| Holder | Shares | % Held |
|---|---|---|
| ICICI Prudential Asset Management Co. Ltd.as of 31 Mar 2024 | 75.78m | 3.16% |
| Life Insurance Corporation of India (Investment Portfolio)as of 13 Sep 2023 | 72.27m | 3.01% |
| SBI Funds Management Ltd.as of 31 Mar 2024 | 54.55m | 2.27% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 42.46m | 1.77% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 25.85m | 1.08% |
| Norges Bank Investment Managementas of 30 Sep 2023 | 24.70m | 1.03% |
| GQG Partners LLCas of 31 Dec 2023 | 23.31m | 0.97% |
| Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 31 Mar 2024 | 22.07m | 0.92% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Mar 2024 | 20.29m | 0.85% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 04 Apr 2024 | 18.61m | 0.78% |
